Reports
Reports
Sale
The global postoperative pain therapeutics market size was valued at USD 38.50 billion in 2023, driven by the increasing incidence of surgical procedures across the globe. The market is expected to grow at a CAGR of 5.79% during the forecast period of 2024-2032, with the values likely to rise from USD 40.73 billion in 2024 to USD 63.89 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Postoperative pain therapeutics aim at relieving suffering, alleviating physiologic, and psychological effects associated with acute pain, boosting recovery, and facilitating better functioning of a patient. It can be oral, topical, or injectable and may include drugs like opioids, NSAIDS or Cox-2 inhibitors. Postoperative pain management generally varies from patient to patient, depending upon the severity and the right combination of treatments that can be administered.
The rising number of surgical procedures across the globe has led to high postoperative pain therapeutics market demand in recent years. Conventionally, opioids have been the leading drug class in postoperative pain treatment. However, recently there have been grave concerns around prevalence of opioid misuse, which has drawn attention towards the development of non-opioid alternatives. In October 2023, the FDA granted its approval for a non-opioid combination therapy. Developed by Hyloris Pharmaceuticals, Combogesic® IV (known as Maxigesic® IV outside the US) is an intravenous (IV) formulation of acetaminophen and ibuprofen for the treatment of postoperative pain.
Apart from systemic pharmacological therapies, which commonly include medications like opioids, NSAIDs and/or acetaminophen, IV ketamine, IV lidocaine, steroids, gabapentin or pregabalin, there has been ample emphasis on developing non-pharmacological as well. Some of the prime examples for pain control include cognitive modalities or mechanical modalities such as transcutaneous electrical nerve stimulation (TENS).
The postoperative pain therapeutics market value is expected to grow further with a wider focus on offering treatment alternatives to several age groups. There has been a significant emphasis on pediatrics amongst researchers, with the rising application of validated pain scales along with relaxation and distraction techniques. Multimodal analgesia, which entails a combination of analgesics and techniques, epidural infusions, peripheral nerve blocks and local infiltration, are some of the most common treatments.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America, led by the United States, dominated the postoperative pain therapeutics market share during the historical period. The increasing prevalence of chronic diseases and rising incidence of surgeries are among the major factors driving the demand in the region. In addition, there has been a key focus on offering quality postoperative care to the patients with the help of developing several novel techniques.
Europe is another major market for postoperative pain therapeutics, accounting for a significant share. Apart from prominent government healthcare services, the region has also been witnessing significant growth with the continuous research and development conducted by influential healthcare companies and research institutions present in the region. In addition, the presence of substantial geriatric population also impacts the market demand.
During the forecast period, the Asia Pacific is projected to witness ample postoperative pain therapeutics market growth. With rising focus on improving the healthcare ecosystem for masses, countries like Japan, China, India, and South Korea have been working on opening new hospitals and clinics, along with improving the infrastructure of existing ones. In addition, there has been significant concentration on fostering research and development in the region. The number of drug approvals has also increased considerably in recent years.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Route of Administration |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Postoperative Pain Therapeutics Market Overview
3.1 Global Postoperative Pain Therapeutics Market Historical Value (2017-2023)
3.2 Global Postoperative Pain Therapeutics Market Forecast Value (2024-2032)
4 Global Postoperative Pain Therapeutics Market Landscape
4.1 Global Postoperative Pain Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Postoperative Pain Therapeutics Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indications
4.2.3 Analysis by Technology
5 Global Postoperative Pain Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Postoperative Pain Therapeutics Market Segmentation
6.1 Global Postoperative Pain Therapeutics Market by Drug Class
6.1.1 Market Overview
6.1.2 Opioids
6.1.3 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
6.1.4 Cyclooxygenase-2-Selective Inhibitors (COX-2) Inhibitors
6.1.5 Other Drug Classes
6.2 Global Postoperative Pain Therapeutics Market by Route of Administration
6.2.1 Market Overview
6.2.2 Injectable
6.2.3 Oral
6.2.4 Topical
6.2.5 Other Routes
6.3 Global Postoperative Pain Therapeutics Market by Distribution Channel
6.3.1 Market Overview
6.3.2 Hospital Pharmacies
6.3.3 Retail Pharmacies
6.3.4 Other Distribution Channels
6.4 Global Postoperative Pain Therapeutics Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Postoperative Pain Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Postoperative Pain Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Postoperative Pain Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Postoperative Pain Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Postoperative Pain Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Teva Pharmaceutical Industries
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Novartis AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Allergan
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Mylan N.V
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Pfizer
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Purdue Pharma
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Janssen Pharmaceuticals
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Endo International
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Pacira Pharmaceuticals
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Egalet Corporation
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 GlaxoSmithKline Plc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Camurus AB
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Pacira BioScience
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 Trevena
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 GlaxoSmithKline Plc.
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Postoperative Pain Therapeutics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
The market attained a value of about USD 38.50 billion in 2023, driven by the rising incidence of surgical procedures across the globe.
The market is anticipated to grow at a CAGR of 5.79% during the forecast period of 2024-2032, likely to reach a market value of USD 63.89 billion by 2032.
The market demand is driven by the growing incidence and seriousness of postoperative pain, high chronic disease rate, introduction of advantageous drugs, and the increasing surgical procedures.
Major market trend involves the application of non-opiod therapies for pain treatment. In October 2023, the FDA granted its approval for a non-opioid combination therapy called Combogesic® IV, developed by Hyloris Pharmaceuticals. It is a formulation of acetaminophen and ibuprofen.
Based on drug classes, it includes opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and acyclooxygenase-2-selective inhibitors (COX-2) inhibitors, among others.
The route of administration can be injectable, oral, and topical, among others.
Major distribution channels include hospital pharmacies, retail pharmacies and others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
Key players involved in the market are Teva Pharmaceutical Industries, Novartis AG, Allergan, Mylan N.V, Pfizer, Purdue Pharma, Janssen Pharmaceuticals, Endo International, Pacira Pharmaceuticals, Egalet Corporation, GlaxoSmithKline Plc., Camurus AB, Pacira BioScience, GlaxoSmithKline Plc., and Trevena.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.